Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39)

To evaluate the addition of the humanized monoclonal antiprogrammed death ligand-1 (PD-L1) antibody, atezolizumab, to platinum-based chemotherapy and bevacizumab in newly diagnosed stage III or IV ovarian cancer (OC). METHODS: This multicenter placebo-controlled double-blind randomized phase III tri...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Moore, Kathleen N., Bookman, Michael, Sehouli, Jalid, Miller, Austin, Anderson, Charles, Scambia, Giovanni, Myers, Tashanna, Taskiran, Cagatay, Robison, Katina, Mäenpää, Johanna, Willmott, Lyndsay, Colombo, Nicoletta, Thomes-Pepin, Jessica, Liontos, Michalis, Gold, Michael A., Garcia, Yolanda, Sharma, Sudarshan K., Darus, Christopher J., Aghajanian, Carol, Okamoto, Aikou, Wu, Xiaohua, Safin, Rustem, Wu, Fan, Molinero, Luciana, Maiya, Vidya, Khor, Victor K., Lin, Yvonne G., Pignata, Sandro
Formato: Artigo
Idioma:Inglês
Publicado em: Wolters Kluwer Health 2021
Assuntos:
RAPID COMMUNICATIONS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8189598/
https://ncbi.nlm.nih.gov/pubmed/33891472
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.21.00306
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados